Several cancer patent to expire in 2018-2020– A great potential for creating value to stakeholder
The COVID-19 pandemic has devastated the entire world and businesses. The Pharma players have also been impacted due to fewer new patient starts during COVID -19.
We have studied the molecule/drugs that have received breakthrough designation and FDA approval in Oncology/Cancer space. It’s been a great opportunity as new molecular entity holds 80% share in the total pipeline products and several patent in cancer space are expected to expire in 2018-2020.
Our universe of study consists of more than 50 molecule/drugs which are launched during 2016-2020 for cancer treatment. Our analysis is based on CAGR of 2016-2019 and launch after Q12018 of drugs’ revenue.
Some of the outperformed drugs based on CAGR are Imfinzi, ALUNBRIG, Verzenio, KISQALI, Nerlynx, CALQUENCE and on basis of launch after Q12018 are PIQRAY, Lutathera, Libtayo, PREVYMIS, Onpattro XOSPATA
For more details please contact email@example.com